Agency Emergency Information Collection Clearance Request for Public Comment, 28633-28634 [2021-11255]
Download as PDF
<![CDATA[
jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 101 / Thursday, May 27, 2021 / Notices
family members of a patient who has
requested the assistance of the Program
in searching for an unrelated donor of
bone marrow or cord blood; persons
with expertise in bone marrow and cord
blood transplantation; persons with
expertise in typing, matching, and
transplant outcome data analysis;
persons with expertise in the social
sciences; basic scientists with expertise
in the biology of adult stem cells;
ethicists, hematology, and transfusion
medicine researchers with expertise in
adult blood stem cells; persons with
expertise in cord blood processing; and
members of the general public to serve
as members. Interested applicants may
self-nominate or be nominated by
another individual or organization.
Individuals selected for appointment
to ACBSCT will be invited to serve for
a term of 2 years, and are eligible to
serve as many as 3 consecutive 2-year
terms. Members appointed as SGEs
receive a stipend and reimbursement for
per diem and travel expenses incurred
for attending ACBSCT meetings and/or
conducting other business on behalf of
ACBSCT, as authorized by 5 U.S.C. 5703
of the FACA for persons employed
intermittently in government service.
The following information must be
included in the package of materials
submitted for each individual being
nominated for consideration: (1) A letter
of nomination stating the name,
affiliation, and contact information for
the nominee, the basis for the
nomination (i.e., what specific
attributes, perspectives, and/or skills
does the individual possess that would
benefit the workings of ACBSCT), and
the nominee’s field(s) of expertise; (2) a
biographical sketch of the nominee; (3)
the name, address, daytime telephone
number, and email address at which the
nominator can be contacted; and (4) a
current copy of the nominee’s
curriculum vitae. Nomination packages
may be submitted directly by the
individual being nominated or by the
person/organization recommending the
candidate.
HHS endeavors to ensure that the
membership of ACBSCT is fairly
balanced in terms of points of view
represented and that individuals from a
broad representation of geographic
areas, gender, and ethnic and minority
groups, as well as individuals with
disabilities, are considered for
membership. Appointments shall be
made without discrimination on the
basis of age, ethnicity, gender, sexual
orientation, or cultural, religious, or
socioeconomic status.
Individuals selected to be considered
for appointment will be required to
provide detailed information regarding
VerDate Sep<11>2014
17:29 May 26, 2021
Jkt 253001
their financial holdings, consultancies,
and research grants or contracts.
Disclosure of this information is
required for HRSA ethics officials to
determine whether there is a conflict
between the SGE’s public duties as a
member of ACBSCT and their private
interests, including an appearance of a
loss of impartiality as defined by federal
laws and regulations, and to identify
any required remedial action needed to
address the potential conflict.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2021–11213 Filed 5–26–21; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: June 23, 2021.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E71A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Patricia A. Gonzales
Hurtado, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of
Extramural Activities, National Institute of
Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room
3E71A, Rockville, MD 20852, 240–627–3556,
Patricia.Gonzales@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: June 28, 2021.
PO 00000
Frm 00109
Fmt 4703
Sfmt 4703
28633
Time: 9:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E71A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Patricia A. Gonzales
Hurtado, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of
Extramural Activities, National Institute of
Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room
3E71A, Rockville, MD 20852, 240–627–3556,
Patricia.Gonzales@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 21, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–11208 Filed 5–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Agency Emergency Information
Collection Clearance Request for
Public Comment
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection projects, the
National Institutes of Health (NIH) will
publish periodic summaries of propose
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
DATES: Comments on the information
collection request must be received on
or before 10 days of this published
notice.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted
within 10 days. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
SUMMARY:
E:\FR\FM\27MYN1.SGM
27MYN1
28634
Federal Register / Vol. 86, No. 101 / Thursday, May 27, 2021 / Notices
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Ms. Mikia P. Currie, Office of
Policy for Extramural Research
Administration, 6705 Rockledge Drive,
Suite 350, Bethesda, Maryland 20892, or
call a non-toll-free number 301–435–
0941 or Email your request, including
your address to
ProjectClearanceBranch@mail.nih.gov.
Formal requests for additional plans and
instruments must be requested in
writing.
SUPPLEMENTARY INFORMATION: Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: Written
comments and/or suggestions from the
public and affected agencies are invited
to address one or more of the following
points: (1) The necessity and utility of
the proposed information collection for
the proper performance of the agency’s
functions; (2) the accuracy of the
estimated burden; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Title of the Collection: Audience
Feedback to Inform Ongoing Messaging
and Strategies for ‘‘Combat COVID’’
Type of Collection: Emergency.
OMB No. 0925–NEW—Federal COVID
Response
Abstract: The Federal COVID
Response (FCR) Team is a cross-agency
resources. Because the COVID–19
treatment landscape continues to evolve
and audience needs continue to change,
it is critical for the FCR Team to collect
routine feedback from the general public
(especially from groups who have not
historically been well-represented in
clinical trials) and healthcare providers
to identify these evolving needs. By
understanding evolving needs, the FCR
team will be able to properly develop
and broadly disseminate relevant
COVID–19 treatment and ACTIV
clinical trial resources. This effort will
require ongoing data collection over the
next 20 months (through the end of
December 2022).
Data collected through this effort will
be used to inform the development and
broad dissemination of Combat COVID
resources, including new or enhanced
messages, materials and/or web pages
(combatcovid.hhs.gov).
The team will employ two strategies
to collect this routine audience
feedback:
1. DATA COLLECTION STRATEGY 1:
Monthly 60-minute virtual audience
feedback teams sessions (focus groups,
in-depth interviews, online bulletin
boards) for rapid testing of new Combat
COVID messages, concepts, ideas,
resources, web pages, and materials.
2. DATA COLLECTION STRATEGY 2:
15-minute custom web surveys to
understand target audiences’ needs and
awareness of Combat COVID over time,
and to inform ongoing messages and
strategies.
partnership that includes the U.S.
Department of Health and Human
Services (HHS), including the National
Institutes of Health (NIH) Office of the
Director, Centers for Disease Control
and Prevention (CDC), the U.S. Food
and Drug Administration (FDA), the
Biomedical Advanced Research and
Development Authority (BARDA), and
the U.S. Department of Defense (DOD).
The FCR Team oversees the ‘‘Combat
COVID’’ initiative—a multifaceted effort
to provide the general public and
healthcare providers with the latest
evidence-based information on COVID–
19 treatments and the Accelerating
COVID–19 Therapeutic Interventions
and Vaccines (ACTIV) clinical trials
(including the combatcovid.hhs.gov
website). The NIH is especially
interested in recruiting participants
from groups who have historically been
underrepresented in clinical trials.
Together with their contractor, the FCR
Team is working to:
• Address participation barriers and
raise awareness of ACTIV clinical trials,
and
• Ensure the general public’s and
health care provider’s needs are met as
it pertains to evidence-based
information on these trials.
The purpose of the information
collection is to collect routine feedback
from the Combat COVID Initiative’s two
target audiences (the general public and
healthcare providers) to identify
evolving needs and better disseminate
relevant information relates to COVID–
19 treatment and ACTIV clinical trial
ESTIMATED ANNUALIZED BURDEN TABLE
Number of
respondents
Type of respondent
Total burden
hours
Consumer Audience Feedback Team Screener (Attachment 1) ....................
HCP Audience Feedback Team Screener (Attachment 2) .............................
Consumer Audience Feedback Activity (Attachments 3 & 5) .........................
HCP Audience Feedback Activity (Attachments 4 & 5) ..................................
Benchmark & Follow-Up Web Surveys—Consumer Audience (Attachment
6) ..................................................................................................................
Benchmark & Follow-Up Web Survey—HCP Audience (Attachment 6) .........
120
40
60
20
1
1
12
12
5/60
5/60
1
1
10
3
720
240
2,000
300
5
5
15/60
15/60
2,500
375
Total ..........................................................................................................
2,540
12,620
........................
3848
Dated: May 20, 2021.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
jbell on DSKJLSW7X2PROD with NOTICES
Average
burden per
response
(in hours)
Number
responses per
respondent
[FR Doc. 2021–11255 Filed 5–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Sep<11>2014
17:29 May 26, 2021
Jkt 253001
PO 00000
Frm 00110
Fmt 4703
Sfmt 4703
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
E:\FR\FM\27MYN1.SGM
27MYN1
]]>Agencies
[Federal Register Volume 86, Number 101 (Thursday, May 27, 2021)]
[Notices]
[Pages 28633-28634]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-11255]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Agency Emergency Information Collection Clearance Request for
Public Comment
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the requirement of the Paperwork Reduction
Act of 1995 to provide opportunity for public comment on proposed data
collection projects, the National Institutes of Health (NIH) will
publish periodic summaries of propose projects to be submitted to the
Office of Management and Budget (OMB) for review and approval.
DATES: Comments on the information collection request must be received
on or before 10 days of this published notice.
ADDRESSES: When commenting, please reference the document identifier or
OMB control number. To be assured consideration, comments and
recommendations must be submitted within 10 days. You may send your
comments electronically to https://www.regulations.gov. Follow the
instructions for ``Comment or Submission'' or ``More Search Options''
to find the information collection document(s) that are accepting
comments.
FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data
collection
[[Page 28634]]
plans and instruments, submit comments in writing, or request more
information on the proposed project, contact: Ms. Mikia P. Currie,
Office of Policy for Extramural Research Administration, 6705 Rockledge
Drive, Suite 350, Bethesda, Maryland 20892, or call a non-toll-free
number 301-435-0941 or Email your request, including your address to
[email protected]. Formal requests for additional
plans and instruments must be requested in writing.
SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: Written comments and/or suggestions
from the public and affected agencies are invited to address one or
more of the following points: (1) The necessity and utility of the
proposed information collection for the proper performance of the
agency's functions; (2) the accuracy of the estimated burden; (3) ways
to enhance the quality, utility, and clarity of the information to be
collected; and (4) the use of automated collection techniques or other
forms of information technology to minimize the information collection
burden.
Title of the Collection: Audience Feedback to Inform Ongoing
Messaging and Strategies for ``Combat COVID''
Type of Collection: Emergency.
OMB No. 0925-NEW--Federal COVID Response
Abstract: The Federal COVID Response (FCR) Team is a cross-agency
partnership that includes the U.S. Department of Health and Human
Services (HHS), including the National Institutes of Health (NIH)
Office of the Director, Centers for Disease Control and Prevention
(CDC), the U.S. Food and Drug Administration (FDA), the Biomedical
Advanced Research and Development Authority (BARDA), and the U.S.
Department of Defense (DOD). The FCR Team oversees the ``Combat COVID''
initiative--a multifaceted effort to provide the general public and
healthcare providers with the latest evidence-based information on
COVID-19 treatments and the Accelerating COVID-19 Therapeutic
Interventions and Vaccines (ACTIV) clinical trials (including the
combatcovid.hhs.gov website). The NIH is especially interested in
recruiting participants from groups who have historically been
underrepresented in clinical trials. Together with their contractor,
the FCR Team is working to:
Address participation barriers and raise awareness of
ACTIV clinical trials, and
Ensure the general public's and health care provider's
needs are met as it pertains to evidence-based information on these
trials.
The purpose of the information collection is to collect routine
feedback from the Combat COVID Initiative's two target audiences (the
general public and healthcare providers) to identify evolving needs and
better disseminate relevant information relates to COVID-19 treatment
and ACTIV clinical trial resources. Because the COVID-19 treatment
landscape continues to evolve and audience needs continue to change, it
is critical for the FCR Team to collect routine feedback from the
general public (especially from groups who have not historically been
well-represented in clinical trials) and healthcare providers to
identify these evolving needs. By understanding evolving needs, the FCR
team will be able to properly develop and broadly disseminate relevant
COVID-19 treatment and ACTIV clinical trial resources. This effort will
require ongoing data collection over the next 20 months (through the
end of December 2022).
Data collected through this effort will be used to inform the
development and broad dissemination of Combat COVID resources,
including new or enhanced messages, materials and/or web pages
(combatcovid.hhs.gov).
The team will employ two strategies to collect this routine
audience feedback:
1. DATA COLLECTION STRATEGY 1: Monthly 60-minute virtual audience
feedback teams sessions (focus groups, in-depth interviews, online
bulletin boards) for rapid testing of new Combat COVID messages,
concepts, ideas, resources, web pages, and materials.
2. DATA COLLECTION STRATEGY 2: 15-minute custom web surveys to
understand target audiences' needs and awareness of Combat COVID over
time, and to inform ongoing messages and strategies.
Estimated Annualized Burden Table
----------------------------------------------------------------------------------------------------------------
Average
Number of Number burden per Total burden
Type of respondent respondents responses per response (in hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
Consumer Audience Feedback Team Screener 120 1 5/60 10
(Attachment 1).................................
HCP Audience Feedback Team Screener (Attachment 40 1 5/60 3
2).............................................
Consumer Audience Feedback Activity (Attachments 60 12 1 720
3 & 5).........................................
HCP Audience Feedback Activity (Attachments 4 & 20 12 1 240
5).............................................
Benchmark & Follow-Up Web Surveys--Consumer 2,000 5 15/60 2,500
Audience (Attachment 6)........................
Benchmark & Follow-Up Web Survey--HCP Audience 300 5 15/60 375
(Attachment 6).................................
---------------------------------------------------------------
Total....................................... 2,540 12,620 .............. 3848
----------------------------------------------------------------------------------------------------------------
Dated: May 20, 2021.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes of Health.
[FR Doc. 2021-11255 Filed 5-26-21; 8:45 am]
BILLING CODE 4140-01-P
